Clinical trials: Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa
Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A study to explore the safety and efficacy of treatment with BDB-001 Injection in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT05103423
- Testing
- BDB-001 Injection
- Where
- 15 sites in China
- Volunteers
- 50 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa
Metformin for the Treatment of Hidradenitis Suppurativa (HS)
A randomized controlled trial investigating the metformin is the treatment for hidradenitis suppurativa. Metformin combined with doxycycline will be compared to the standard treatment of doxycycline monotherapy for HS severity…
- Trial name
- NCT04649502
- Testing
- Metformin
- Where
- Netherlands
- Volunteers
- 62 people
- Sponsor
- K.R. van Straalen
Hidradenitis Suppurativa (HS)
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe…
- Trial name
- NCT07489573
- Testing
- Secukinumab
- Where
- 10 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
The Safety and Efficacy of Roflumilast Foam in HS
This study investigates the efficacy of topical roflumilast foam in patients with HS.
- Trial name
- NCT07263230
- Testing
- Roflumilast 0.3% topical foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- LOTUS (NCT06603077)
- Testing
- AVTX-009 Regimen 1, AVTX-009 Regimen 2
- Where
- 89 sites in United States, Australia and 11 more
- Volunteers
- 253 people
- Sponsor
- Avalo Therapeutics, Inc.
Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa Wound Care
The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform [ovine forestomach], Hydrofera Blue [methylene blue and gentian violet], and Hypafix tape.
- Trial name
- NCT04354012
- Testing
- methylene blue, gentian violet, and ovine forestomach wound dressings
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on…
- Trial name
- ANIMA - Italy (NCT07543419)
- Where
- 16 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS), Fecal Microbiota Transplantation (FMT)
FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study
The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge.
- Trial name
- FESTIVAL (NCT07668713)
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- 7 sites in France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hidradenitis Suppurativa (HS)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
This study is a Phase Ic/II clinical trial conducted in Chinese patients with moderate-to-severe hidradenitis suppurativa (HS), aiming to evaluate the safety and efficacy of LT-002-158 tablets in the treatment of…
- Trial name
- NCT06932003
- Testing
- LT-002-158 Tablets
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Hidradenitis Suppurativa
Aviclear for Hidradenitis Suppurativa (HS)
The objective is to evaluate the safety and efficacy of the Cutera 1726 nm laser system (also referred to as AviClear) for the treatment of HS.
- Trial name
- NCT06801795
- Testing
- AviClear
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Miami
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week…
- Trial name
- STOP-HS1 (NCT05620823)
- Testing
- Povorcitinib
- Where
- 104 sites in United States, Austria and 10 more
- Volunteers
- 608 people
- Sponsor
- Incyte Corporation
Healthy Volunteer, Atopic Dermatitis
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases.
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Trial name
- NCT04772885
- Testing
- KT-474
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Hidradenitis Suppurativa (HS)
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment…
- Trial name
- ILLUMINATE-SA (NCT06785779)
- Testing
- Secukinmab
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
This study assesses Humira's® real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- SOLACE (NCT02896920)
- Where
- 22 sites in Canada
- Volunteers
- 165 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa (HS)
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
- Trial name
- NCT07783542
- Testing
- ORKA-002
- Where
- 25 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Oruka Therapeutics, Inc.
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD II (NCT04242498)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 509 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa (HS)
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
- Trial name
- SHARPS (NCT02808975)
- Testing
- Adalimumab
- Where
- 55 sites in United States, Belgium and 21 more
- Volunteers
- 206 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
The study is a randomized, proof of concept study. 30 patients aged 18 and over with HS will be included in this single center, randomized, double-blind, parallel-group study.
- Trial name
- NCT05997277
- Testing
- Deucravacitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT06799000
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin.
- Trial name
- WMCREI (NCT07155239)
- Testing
- AviClear Lase Treatment
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wynn Medical Center